Amorfix Life Sciences Ltd. has signed an agreement with a major global pharmaceutical company providing access to its EP-AD assay technology for an Alzheimer's disease diagnostic assay for Phase I studies. Terms of the agreement were not disclosed.
The EP-AD diagnostic assay can identify early-stage AD patients and patients with mild cognitive impairment (MCI) who are at high risk of developing AD. The EP-AD assay measures levels of Abeta aggregates, a biomarker of the disease. The pharma company will complete assay optimization and validation for a clinical trial investigating the effects of a new therapeutic for the treatment of AD.
"We are very excited to be working with a world-class pharmaceutical company with the resources and expertise to assist in the further development our human Alzheimer's disease diagnostic assay technology. The Company has worked very hard to create a diagnostic test that can identify patients with early-stage disease and we are gratified to have the opportunity to assist in the clinical development of new therapeutics that may offer improved treatment options for Alzheimer's disease patients" said Dr. Robert Gundel, Amorfix president and chief executive officer. "In addition, this agreement is an example of our business plan to establish effective partnerships and strategic alliances with companies that have the resources and expertise to help advance our products to clinical development and commercialization.”
Amorfix Enters AD Assay Pact
By Kristin Brooks
Published January 22, 2014
blog comments powered by Disqus